FDA refuses to review Moderna’s mRNA flu vaccine

Moderna, a leading biotechnology company known for its pioneering work in mRNA technology, has been dealt a significant setback by the U.S. Food and Drug Administration (FDA). The company announced on Tuesday that it received a "refusal-to-file" (RTF) letter from the FDA’s Center for Biologics Evaluation and Research (CBER) regarding its investigational mRNA-based influenza vaccine, mRNA-1010. This unexpected rejection prevents the FDA from initiating a substantive review of Moderna’s Biologics License Application (BLA), despite the vaccine having demonstrated robust efficacy in Phase 3 trials and being accepted for review by regulatory bodies in the European Union, Canada, and Australia.

The RTF letter, a rare procedural hurdle, cited a singular reason for the refusal: Moderna’s choice of a comparator vaccine in its pivotal Phase 3 study. According to Moderna, the FDA indicated that the trial lacked an "adequate and well-controlled" comparator arm because it "does not reflect the best-available standard of care," particularly for adults over 65. Specifically, the FDA took issue with the use of Fluarix, a standard-dose seasonal influenza vaccine, arguing that a high-dose vaccine should have been used as the comparator for the elderly population, which the agency now considers the "best-available standard of care" for this demographic. Moderna has vehemently contested this rationale, asserting that neither existing regulations nor FDA guidance documents explicitly mandate the use of a "best-available standard of care" comparator. Furthermore, the company emphasized that the RTF letter did not identify any specific safety or efficacy concerns with mRNA-1010 itself.

A Deep Dive into the Refusal-to-File Decision

A refusal-to-file letter is an uncommon occurrence in the drug and biologic approval process. A 2021 study analyzing 2,475 applications found that only about 4% received an RTF letter, underscoring the unusual nature of this decision for Moderna. Such a letter signifies that the FDA has determined an application is incomplete or fundamentally flawed in a way that prevents a meaningful scientific review. For companies, an RTF can lead to significant delays, increased development costs, and a loss of market momentum.

The FDA’s objection hinges on the "comparator arm" used in Moderna’s Phase 3 clinical trial for mRNA-1010. Clinical trials often compare a new treatment or vaccine against an existing, approved standard to assess its relative efficacy and safety. For influenza vaccines, especially in vulnerable populations like adults aged 65 and older, high-dose or adjuvanted vaccines (e.g., Fluzone High-Dose Quadrivalent, Fluad Quadrivalent) are often recommended by advisory bodies like the CDC, as they typically elicit a stronger immune response and provide better protection in this age group compared to standard-dose vaccines. The FDA’s stance implies that to demonstrate a meaningful clinical benefit for seniors, Moderna should have benchmarked its new vaccine against these enhanced efficacy options.

Moderna, however, argues that its trial design was consistent with prior discussions with CBER. The company pointed out that its pre-Phase 3 and pre-submission consultations with the FDA did not raise these specific concerns about the comparator choice to the extent that it would warrant an RTF. In April 2024, Moderna submitted its Phase 3 study protocol to CBER for review. While CBER did recommend considering a high-dose vaccine for the comparator arm in adults over 65 at that time, Moderna stated that the agency did not raise any objections or issue clinical hold comments indicating that the chosen trial design would be inadequate for review. Following the completion of the trial, a pre-submission meeting with CBER also reportedly did not signal an impending refusal to review the application. This discrepancy between earlier feedback and the final RTF letter is a core point of contention for Moderna.

Efficacy Profile of mRNA-1010

Despite the regulatory roadblock, Moderna’s mRNA-1010 has demonstrated promising efficacy data. In its Phase 3 trials, the vaccine exhibited a 26.6% higher relative vaccine efficacy compared to the standard-dose comparator. This efficacy was consistent across various individual influenza strains: 29.6% for A/H1N1, 22.2% for A/H3N2, and 29.1% for B/Victoria. Crucially, for the very demographic at the heart of the FDA’s objection, adults 65 and older, mRNA-1010 showed 27.4% relative efficacy. These results, if accepted for review, would position mRNA-1010 as a potentially significant advancement in influenza prevention, especially as it would represent the first mRNA-based influenza vaccine globally. The ability of mRNA technology to rapidly adapt to circulating strains could offer a distinct advantage over traditional vaccine production methods.

A Timeline of Key Events and Interactions

The journey of mRNA-1010 to regulatory submission has been marked by several interactions with the FDA:

April 2024: Moderna submits its Phase 3 study protocol for mRNA-1010 to CBER for review. CBER recommends using a high-dose vaccine for adults over 65 in the comparator arm but does not raise objections or issue clinical hold comments regarding the overall adequacy of the trial design.
Late 2024 / Early 2025: Moderna conducts its Phase 3 trials, using Fluarix (a standard-dose vaccine) as the comparator, consistent with what it believed was an agreed-upon protocol.
Pre-submission Meeting (Date not specified but prior to RTF): Moderna holds a pre-submission meeting with CBER, which, according to the company, provided no indication that the application would be refused for review.
February 2025: Robert F. Kennedy Jr. assumes office as HHS Secretary under the Trump administration, initiating significant shifts in U.S. vaccine policy.
August 2025: The Department of Health and Human Services (HHS) cancels $500 million in BARDA (Biomedical Advanced Research and Development Authority) funding specifically earmarked for mRNA vaccine development. This move signals a broader policy shift away from supporting mRNA platforms.
December 2025: Children’s Health Defense, an organization founded by Robert F. Kennedy Jr., formally petitions the FDA to revoke the emergency use authorizations and full licenses for Moderna and Pfizer’s COVID-19 mRNA vaccines, citing various safety concerns.
Early February 2026 (Implied): Moderna receives the RTF letter for mRNA-1010. The letter is signed by CBER Director Vinay Prasad, a known critic of mRNA vaccines.

This chronology suggests a regulatory environment increasingly shaped by a skeptical stance towards mRNA technology and potentially, an overarching political agenda influencing public health policy.

Political and Internal FDA Dynamics

The decision to issue an RTF letter for mRNA-1010 has ignited concerns about potential political interference in the scientific review process at the FDA. The decision comes under the Trump administration, with Robert F. Kennedy Jr. serving as HHS Secretary. Kennedy, a vocal vaccine skeptic and proponent of alternative health views, has overseen substantial changes to U.S. vaccine policy since taking office in February 2025. His tenure has been marked by actions perceived as undermining established vaccine science, including the cancellation of BARDA funding for mRNA vaccines and the aforementioned petition by Children’s Health Defense against licensed COVID-19 mRNA vaccines.

Adding another layer of controversy, the RTF letter was signed by CBER Director Vinay Prasad. Prasad, a physician and academic, has been a prominent and often critical voice regarding mRNA vaccines and drug development more broadly. His involvement in this specific decision, especially given the reported internal dynamics, raises questions about the independence of the regulatory process.

A report by STAT, a leading health and medicine news organization, revealed significant internal disagreement within CBER regarding Moderna’s application. According to STAT, "Three agency officials familiar with the matter told STAT that the team of career scientists was ready to review Moderna’s application, and that David Kaslow, the head of the vaccine office, wrote a detailed memo explaining why the FDA should embark on the review." This suggests that the decision to issue the RTF letter may have bypassed or overruled the consensus of experienced FDA career staff who believed the application was complete and merited a full review. Such an override, if true, could signal a troubling precedent where political appointees or department heads can unilaterally block scientific review processes based on non-scientific or policy-driven grounds, potentially eroding the FDA’s reputation for independent, science-based decision-making.

Official Reactions and Broader Implications

Moderna’s CEO, Stéphane Bancel, expressed strong dissatisfaction with the FDA’s decision: "It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting. We look forward to engaging with CBER to understand the path forward as quickly as possible so that America’s seniors, and those with underlying conditions, continue to have access to American-made innovations." Bancel’s statement underscores the company’s belief that it followed established protocols and that the FDA’s current stance is inconsistent with prior guidance.

The refusal to review mRNA-1010 has several significant implications:

For Moderna: It represents a substantial delay in bringing a key product in its non-COVID mRNA pipeline to market. Moderna has invested heavily in diversifying its mRNA platform beyond COVID-19, and influenza vaccines are a cornerstone of this strategy. The delay could impact revenue projections and investor confidence.
For mRNA Technology: While mRNA vaccines proved revolutionary during the COVID-19 pandemic, this decision could cast a shadow over their broader acceptance and regulatory pathway for other diseases. It could create uncertainty for other companies developing mRNA-based therapeutics and vaccines, suggesting a more challenging regulatory environment than previously anticipated.
For Public Health: A delay in the approval of a potentially more effective influenza vaccine means that the public, particularly vulnerable populations like the elderly, will not have access to this innovation in the near future. Given the annual burden of influenza, new and improved vaccines are crucial for public health.
For Regulatory Independence: The reported overruling of career scientists and the backdrop of the HHS Secretary’s known skepticism about mRNA vaccines raise serious questions about the FDA’s independence and its ability to make purely scientific, unbiased decisions. This could lead to a crisis of confidence in the regulatory body among the scientific community and the public.
Precedent Setting: The FDA’s argument about the "best-available standard of care" could set a new and potentially stringent precedent for future vaccine and drug development trials, particularly for therapies targeting vulnerable populations. Companies may need to re-evaluate their trial designs significantly to anticipate such requirements, even if not explicitly stated in current guidance.

The Path Forward

Moderna has formally requested a meeting with the FDA to discuss the RTF letter and understand the agency’s specific concerns and the path forward. Such meetings are standard procedure after an RTF and aim to clarify the deficiencies identified and outline the steps required for a resubmission. This could involve conducting additional clinical trials, performing new analyses of existing data, or negotiating a revised trial design with the FDA. However, given the political undertones and the reported internal disagreements, the resolution process may be protracted and complex.

The situation surrounding Moderna’s mRNA-1010 vaccine transcends a mere administrative hiccup; it highlights a complex interplay of scientific rigor, evolving regulatory expectations, and potentially, political influence on public health policy. As the world continues to grapple with infectious diseases, the swift and unbiased review of innovative medical solutions remains paramount. The outcome of Moderna’s engagement with the FDA will not only determine the future of mRNA-1010 but also serve as a crucial indicator of the regulatory landscape for future biotechnological advancements in the United States.